British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...

GSK PLC GSK shares rose 2.90% to £13.83 Monday, on what proved to be an all-around great trading session for the stock market ...

Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...

GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...